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Abstract
Substantial effort in recent years has been devoted to constructing and analyzing large-scale gene
and protein networks based on 'omic data and literature mining. These interaction graphs provide
valuable insight into the topologies of complex biological networks, but are rarely context-specific
and cannot be used to predict the responses of cell signaling proteins to specific ligands or drugs.
Conversely, traditional approaches to analyzing cell signaling are narrow in scope and cannot
easily make use of network-level data. Here we combine network analysis and functional
experimentation using a hybrid approach in which graphs are converted into simple mathematical
models that can be trained against biochemical data. Specifically, we created Boolean logic
models of immediate-early signaling in liver cells by training a literature-based prior knowledge
network against biochemical data obtained from primary human hepatocytes and four
hepatocellular carcinoma cell lines exposed to combinations of cytokines and small-molecule
kinase inhibitors. Distinct families of models were recovered for each cell type that clustered
topologically into normal and diseased sets. Comparison revealed that clustering arises from
systematic differences in signaling logic in three regions of the network. We also infer the
existence of a new interaction involving Jak-Stat and NFκB signaling and show that it arises from
the polypharmacology of an IκB kinase inhibitor rather than previously unidentified protein-
protein associations. These results constitute a proof-of-principle that receptor-mediated signal
transduction can be reverse engineered using biochemical data so that the immediate effects of
drugs on normal and diseased cells can be studied in a systematic manner.
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Quick Guide to Equations and Assumptions
We start with a Prior Knowledge Network (PKN) comprising a “signed and directed” node-
edge graph that depicts interactions among proteins as arrows so that substrate-product and
activation-inhibition relationships are captured: Raf→MEK→ERK for example. The 78
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node, 112 edge PKN in this paper came from the Ingenuity database with manual additions.
A PKN cannot be compared directly to cell response data because a model is needed to
specify input-output relationships. Here we use a simple Boolean formalism, in which the
state of a nodes is either 0 or 1 (“off” or “on”), and nodes interact via AND/OR/NOT logical
operators. In this formalism, if EGFR OR IR is active then MEK is active, etc. Conversion
of a PKN into a Boolean model proceeds as follows. Network preprocessing specifies
proteins to be measured or perturbed experimentally (so-called designated nodes) and then
compresses the PKN based on two criteria (1): (a) nodes that are not directly or indirectly
connected to designated nodes are eliminated (because we have no data on them) (b)
cascades in which a undesignated nodes impinge on designated nodes are simplified; for
example, if Raf and ERK are designated, but MEK is not, then Raf→MEK→ERK is
replaced by Raf→ERK. Logical expansion computes all possible combinations of logic
gates compatible with the compressed network. Each interaction in the PKN (hyperedges in
graph theory) can give rise to multiple logical connections so that if two edges link into
ERK (e.g. Raf →ERK and NFκB →ERK) we would generate three logic interactions: (i)
Raf →ERK, (ii), NFκB →ERK and (iii) Raf AND NFκB →ERK. An OR gate (Raf OR
NFκB →ERK) simply corresponds to (i) plus (ii). In our compressed PKN, 32 nodes and
128 logical interactions (hyperedges) give rise to 2128 = ~1038 possible models, each of
which is evaluated against data. Training a family of possible models against data involves
propagating the input signals along the logical network until all nodes reach inter-consistent
values (a logical steady state); models are then compared to experimental measurements.
Raw data are processed so that arbitrary intensity measures from xMAP sandwich immuno-
assays are converted into values between 0 and 1 based on various standards, a procedure
that we have previously described in detail (1). For quantitative analysis of model/data
match, the deviation (mean squared error; MSE) between data and a specific model is
computed as  is predicted by the logical
steady state of the model and  is the discretized data for assay l recorded at time
t under the kth experimental condition. Values incompatible with a logical steady state are
penalized as though they represent a mismatch between simulation and experimental data.
We seek the simplest models consistent with data, using a bipartite objective function: Θ =
MSE + α ΘS where ΘS is model size and α is an adjustable parameter. We have shown that
models identified using this objective function are similar in their numbers of edges and
goodness of fit across a wide range of values for α (1); in the current paper we set α=
0.0001.
The training procedure consists of searching across 2128 models by the objective function
using a standard genetic algorithm (2). Model training was iterated 50–100 times for each
set of data. Because of the stochastic nature of the genetic algorithm and the non-
identifiability of the models given data, different solutions were recovered each time. In
common with most work on network inference, we addressed non-identifiability by
analyzing families of models instead of single solutions; in the current work models within 1
% MSE of the best-fit model constituted the “consensus.” For subsequent analysis, the
distance between two sets of models j and k was computed as  is
the frequency of the ith hyperedge in the kth model set. Distances were normalized with
respect to the distance between hepatocyte and AvgHCC models (Table S1).
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INTRODUCTION
The availability of high throughput interaction data has led to the creation of methods for
summarizing and exploring networks using node-edge graphs. In these graphs, genes or
proteins are represented by nodes (vertexes) and interactions by edges (3, 4)). The
underlying interaction data are diverse and include manual or automated text mining of the
literature (5, 6), genetic interactions obtained from gene deletion sets, and physical
interactions identified by large-scale mass spectrometry or two-hybrid analysis (4, 7).
Interactions in node-edge graphs can be undirected (denoting an unspecified interaction),
directed but unsigned (denoting substrate-product relationships) or directed and signed
(denoting both substrate-product and inhibition-activation relationships); the latter are
particularly useful because they capture biochemical causality. For protein data, graphs
comprising undirected edges are typically called Protein Interaction Networks (PINs)
whereas those with signed directed edges are known as Protein Signaling Networks (PSNs).
Most work on PINs and PSNs to date has focused on adding as much data as possible, often
from more than one organism or type of experiment, so as to construct large networks with
the greatest possible scope and the greatest number of interactions per node (increasing the
“degree” of the network); the culmination of this effort is a proposed “Human Interactome”
covering all known gene products (8).
In cancer biology, comparative analysis is the natural focus of “conventional” low-
throughput studies of signal transduction with particular attention paid to differences in
cellular responses to ligands or drugs in different cell types. In most cases, these differences
reflect changes in the abundance or activity of signaling proteins (or of their substrates),
features that could in principle be depicted by the strength of an edge in a network graph.
However, existing PSNs and PINs do not encode the activities of proteins in cells that have
been exposed to specific activators or inhibitors. A dearth of data on context-specific
interactions makes it difficult to compare normal and diseased cells or diseased cells from
different tumors. Cell- and state-specific information has been added to network graphs
using gene expression data (3, 7, 9), but few attempts have been made to reconstruct
comparative networks using biochemical data.
In this paper we attempt to combine concepts from global network discovery and traditional
biochemistry by constructing comparative network models of signal transduction in normal
and transformed liver cells. Starting with a prototypical network derived from the literature
(which we will refer to as a prior knowledge network or PKN), we first constructed a set of
all Boolean models compatible with the PKN, used the model “superstructure” to guide the
collection of biochemical data on multiple nodes in the network across multiple cell types,
and then trained the superstructure against data to uncover underlying differences in
signaling logic among cell types. The net result is a computational representation of a
signaling network that focuses on activity rather than literature association or physical
interaction and that is explicitly comparative.
A first essential step in adding activity data to networks is to convert PKNs into models in
which it is possible to compute input-output (I/O) characteristics (1). In this paper we use a
two-state (Boolean) logical formalism in which each node can have only two states, 0 or 1,
but having a 1 at the output can depend on having a 1 at one of several inputs (an OR gate),
all inputs (an AND gate), or 0 and 1 inputs in any combination. Boolean models have the
advantage that they have no continuous free parameters and their topologies can be trained
efficiently using data (1), a task that is harder with large differential equation models (10).
However, we recognize that real biological systems exhibit dose response behavior that is
only poorly approximated by Boolean logic. Thus, a major question at the outset of this
work was whether the strengths of Boolean modeling with respect to computational
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simplicity would outweigh its weaknesses. It seemed possible that the crudeness of the
Boolean on/off approximation would overwhelm any differences we might measure
experimentally from one cell type to the next. Conversely, success in creating comparative
models would constitute a proof-of-principle for the approach.
We therefore applied Boolean modeling to distinguishing patterns of immediate early
signaling in normal and transformed cells, represented here by primary human hepatocytes
and HepG2, Hep3B, Focus and Huh7 liver cancer cell lines. Liver cancer (which is
dominated by hepatocellular carcinoma [HCC]) is the third most common cause of cancer
death in humans (11) and is known to involve alterations in the EGF-Ras-MAPK, AKT/
mTOR, Jak/Stat and NFκB cascades (12). Thus, we aimed to collect multivariate data on the
activities of these pathways in normal and transformed hepatocytes. We show that it is
possible to assemble predictive network models that are specific to each cell type, cluster
models based on topology and uncover consistent biochemical differences between
transformed and normal cells. By identifying an interaction missing from the starting PKN
but supported by data, we also uncover a poorly documented off-target effect of a drug
being developed for asthma and inflammation (13, 14). Our findings demonstrate that
discrete logical modeling can capture cell-type specific biochemical relationships, raising
the possibility of constructing large comparative models of signal transduction in normal
and diseased cells.
MATERIALS AND METHODS
Data generation
HepG2 and Hep3B, HuH7, and Focus cells were plated in 96-well plates coated with
collagen type I (Becton Dickinson) with 100 µl phenol-free Williams’ Medium E (WEM,
Sigma-Aldrich) with supplements (15). Freshly pre-plated primary human hepatocytes were
purchased from CellzDirect (Research Triangle Park, NC) and cultured overnight on
collagen, starved for 6 hours in 95 µl of WEM, exposed to kinase inhibitors for 40 min. and
then to ligands for 25 min. All cells were lysed in 90 µl of manufacturer’s xMAP buffer
(Bio-Rad) and intracellular signals measured using a Luminex instrument (Luminex, Austin,
TX) and 16-plex phospho-protein bead sets (Bio-Rad; see Supplementary material).
Different dilutions of cell extract were required for all 16 signals to be in the linear range.
HepG2 and Hep3B cell lines were obtained directly from ATCC; Huh7 and Focus cells (16),
which are not available from ATCC, were obtained from Prof. Jack Wands. Cells were
expanded once to create master stocks from which working cultures were periodically
established; no lines were serially passage longer than three weeks. ATCC cell lines are
validated by the provider (17); no testing was performed on the other lines. Freshly plated
human hepatocytes were tested for contaminants as described in (15).
Reagents
To minimize experimental variability, samples were processed in parallel and common
stocks of cytokines, inhibitors, and assay reagents used throughout (see Supplementary
materials). Recombinant Jak2 and IKK-2 obtained from Cell Signaling Technology were
preincubated with kinase inhibitors for 5 min. in manufacturer’s buffer with 20µM ATP and
FLT3 as Jak2 substrate or Iκb as a IKK-2 substrate. Phosphorylation was assayed using a
time resolved fluorescence plate reader (PerkinElmer Victor 3) and apparent IC50 calculated
from the activity A, where A = (I +[drug] / IC50H)−1 and H is the apparent Hill coefficient.
Ki for TPCA-1 was calculated using the Cheng-Prusoff equation, Ki = IC50 / (1+[ATP] /
KM) where KM (for ATP) was 0.43µM for Jak2 and 0.91 µM IKK-2.
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Data handling
Data was processed and visualized using DataRail software (18) (19) with xMAP
measurements normalized to a value between 0 and 1 (1).
Network construction and model calibration
The starting Protein Signaling Network (PKN) was constructed with ProMoT (20) using the
database of Ingenuity Systems (21) supplemented manually. Modeling was then performed
using our MATLAB toolbox CellNetOptimizer (CellNOpt; (22).
RESULTS
The dynamics of immediate-early signaling pathways was probed using a combinatorial
experimental protocol (23): primary human hepatocytes and four HCC lines were treated
with IL1α, IL6, TGFα, TNFα and Insulin (15), in the presence and absence of small
molecule kinase inhibitors of IKK, MEK and PI3K and 16 intracellular signaling proteins
were then assayed in cell extracts using multiplex sandwich immuno-assays (xMAP assays;
Luminex Inc. Fig. 1 and S1; (15). Our use of kinase inhibitors and phospho-protein
antibodies naturally focused the analysis on the druggable kinome (24) but similar analysis
with other classes of drugs and signaling proteins is also possible. The experiments
generated five sets of ligand-response data (for HepG2, Focus, Hep3B, Huh7 cell lines;
“hepatocytes” refers to primary human hepatocytes); a sixth dataset (AvgHCC) was
synthesized by arithmetically averaging data from the four tumor lines and attempts to
capture biochemistry common to all cell lines.
All Boolean models compatible with a PKN of receptor-mediated signaling that included 78
nodes and 112 interactions was processed using freely available software of our own design,
CellNetOptimizer (CellNOpt; (1). This yielded an ensemble of ~1038 models having 128
AND or OR gates with different connectivity or logic. The ensemble of ~1038 models was
compared to each of six sets of experimental data (representing five cell types and the
average) using a bipartite objective function that minimized the deviation between model
and data while penalizing model size (Fig. 2). For any single data set optimization returned
multiple models that differed slightly in topology and logic but had nearly the same value of
the objective function (therefore making them indistinguishable with respect to data). Such
“non-identifiability” is common in network inference and we therefore retained a family of
best-fit models for each cell type differing by 1% in goodness of fit (see equations box for
details).
Because Boolean models lack continuous parameters (akin to the rate constants in an
differential equation network), it is not necessarily true that training will yield a model
having a substantially better fit to data than the PKN, but this was the case with our data and
models: the untrained ensemble containing all possible interactions and logic exhibited a
poor fit (39–47 % MSE error across all data sets, Fig. 3) whereas families of trained models
exhibited much better fit (9% to 13 % MSE error, see Figs. 3 and S2). We performed cross-
validation and statistical tests to show that trained models were predictive of real data and
were non-random (Figs. S3, S4, S5). Moreover, models trained against individual HCC cell
lines were all better than the starting ensemble at predicting AvgHCC data (which was not
used in training; 10–14 % MSE error, Fig. 3a). When the fit between models and data
corresponding to individual ligands or biochemical assays was examined, levels of error
were relatively low except in the case of p53 and IRS1s, which exhibited poor fits across all
conditions (Fig. 3b and S6). This almost certainly arises because the PKN represents p53
biology in an imprecise manner and annotation of IRS1 modification is incomplete. These
Saez-Rodriguez et al. Page 5
Cancer Res. Author manuscript; available in PMC 2012 August 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
are areas in which improved PKNs would clearly be useful. Nonetheless, we conclude that
model training recovers substantially better network representations that the starting PKN.
Signaling network properties determined from data-trained logical models
In our procedure, training a PKN-based Boolean model against data improves the goodness
of fit by removing unused edges. However, connectivity varied significantly with cell type:
85 of 128 possible gates were present in the superposition of all models in all cell types
(involving ~90% of the interactions not removed in the preprocessing), but only seven gates
were common to all models (Figs. 4 and S7). We therefore concluded that the primary
deficiency of the literature-derived PKN with respect to our data is not the presence of true
false-positive interactions (since some support can be found for most edges in data) but
rather an absence of cell-type specificity.
To compare the topologies of models for all six data sets we computed pairwise distances by
enumerating edges that differed between averaged best-fit models (see methods and Table
S1 for details). HCC-derived models clustered together, with models built from AvgHCC
data in the middle of the cluster, and well separated from models of primary hepatocytes
(Fig. 5a). Models of Focus cells were farthest from primary cell models and HepG2 models
were closest, in agreement with a classification of HCC lines proposed previously (25–27)
(Fig. 5b). Moreover, the pattern of clustering derived from network topology was generally
similar to pattern computed from transcriptional profiles. While the goal of logical modeling
is not to generate cluster diagrams (being focused instead on the biochemistry of signal
transduction) the similarities between clusters generated using transcript profiling and
logical models suggest that the biochemical processes covered in our networks are
representative of broader differences across cell lines.
Pathway differences in signaling networks among primary and transformed cells
Next we asked which interactions or logical gates were consistently present or absent when
all possible models for one cell type were compared to all models of another cell type. This
is a conservative approach that accounts for the inability of training to uniquely specify a
model for each cell type based on available data. We observed that one interaction was
absent from all models of HCC cells while being present in all models of primary
hepatocytes whereas six interactions had the opposite property, being present only in models
of HCC cells (Fig. 6). These differential interactions affected three regions of the signaling
network. First, whereas the EGFR ligand TGFα caused ERK activation in all cell types, up-
regulation of Hsp27-S78 phosphorylation (presumably by PRAK kinase, which lies
downstream of ERK) was observed only in primary cells (differential interactions 1–2). In
two of four HCC cell lines (Focus and Huh7) Hsp27-S78 was phosphorylated to a
significant degree but it was p38-rather than ERK-dependent (Fig. S7). These findings are
consistent with a reported association between low levels of Hsp27-S78 phosphorylation and
tumor progression in HCC our data shows that the situation is more complex than previously
thought (28) potentially involving a switch in Hsp27 kinases. A second significant
difference between primary and HCC cells involved a change in the inferred logic of the
IKK-NFκB pathway: in primary hepatocytes Iκb-S32/S36 phosphorylation (a signal for Iκb
degradation and consequent nuclear localization of NFκB) required TNFα and an activator
of PI3K such as TGFα (differential interactions 3–4). In contrast, in HCC lines only TNFα
was required, implying differential control over canonical NFκB-mediated signaling.
The third significant difference involved phosphorylation of PI3K/AKT and GSK3-S9/S21
in Insulin-treated HCC cells but not in primary hepatocytes (differential interactions 5–8).
AKT is a potent pro-survival kinase and its phosphorylation of GSK3 on S9/S21 is known to
down-regulate GSK3 activity and promote nuclear localization of β–catenin, NFAT and
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other pro-growth factors (29). Insulin receptor substrate 1 (IRS-1) is over-expressed in HCC
cell lines (30) and it is possible that this shifts Insulin receptor (IR) signaling (or signaling
by Insulin-like growth factor receptors, which are also present in these cells) from a
metabolic function in normal liver (31) to a pro-survival function in tumors that involves
elevated PI3K/AKT and GSK3 phosphorylation. Increased AKT activity is also expected in
tumors due to downregulation of proteins such as the p85 subunit of PI3K, a common
feature of HCC (32).
Overall we conclude that direct comparison of Boolean models was successful in identifying
activity-dependent differences among normal and diseased cells that are hard to capture in
PINs and PKNs assembled from physical interaction or steady-state proteomic and
expression data. At the same time, we note that the Boolean models in this paper capture
signaling at a single time point only, and only describe ligand-driven changes in
phosphorylation. The absence of an IR→PI3K link in the inferred map for hepatocyte
signaling (despite the known function of IR in the liver (32)) might arise because basal
levels of AKT phosphorylation are high in these cells, making it difficult to detect ligand-
dependent super-activation, or because we assayed cells at the wrong point in time (methods
for incorporating time-series data into calibrated Boolean models are in development).
However, Boolean modeling correctly inferred an EFGR→PI3K link in both transformed
and primary cells and follow-up experiments suggest that there is indeed a greater
propensity of tumor cells to respond to insulin by activating AKT.
Identification and testing of model-inferred novel pathway interactions
The model training described above focused on eliminating interactions present in the PKN
but not supported by data. However, it is likely that PKNs also lack interactions that are
supported by data. Indeed, we observed the single largest error in all models with respect to
data involved an observed inhibition of Stat3-Y705 phosphorylation by the IKK inhibitor
TPCA-1 under conditions of IL6 stimulation (Fig. 3b). TPCA-1 is reported to be a potent
and selective inhibitor of human Iκbkinase-2 (IC50 = 18 nM for IKK-2 and 400nm for
IKK-1) and was originally identified by GlaxoSmithKline in a drug-discovery effort focused
on rheumatoid arthritis and airway inflammation (13, 14). The inhibition of Stat3-Y705
phosphorylation by TPCA-1 can be explained in a Boolean model by adding an interaction
between IKK and Stat3 (see Fig. 4); this reduced the MSE error of all model families by
~5%. While an IKK → Stat3 edge might represent a physical interaction, an alternative
explanation is that prior knowledge about TPCA-1 is incorrect and the drug actually inhibits
Jak2, the known kinase for Stat3. To distinguish among these possibilities we performed in
vitro activity assays of purified Jak2 and IKK-2 in the presence of TPCA-1 or BMS345541,
an IKK-2 inhibitor having a distinct chemical structure (IC50~300 nM). BMS345541 does
not compete with ATP (it binds to homologous allosteric sites on IKK-1 and IKK-2) and
presumably has different off-target effects. We found TPCA-1 to be nearly as potent an
inhibitor of Jak2 in vitro (Ki ~9 nM) as of IKK-2 (Ki~1.6 nM) its known target but
BMS345541 was IKK-selective. Moreover, in IL6 stimulated cells, BMS345541 reduced
phosphorylation of the IKK substrate Iκbα on Ser32/Ser36 but had no detectable effect on
the level of phosphorylated Stat3- Y705 (Fig. 7). We conclude that Jak2 is a target of
TPCA-1 (consistent with a recent kinome profile (33), and that Boolean network inference
therefore identified a new target for the drug rather than a new protein-protein interaction.
DISCUSSION
Despite the relative crudeness of two-state logical approximations of biochemical reactions,
this paper demonstrates that is possible to use Boolean modeling in combination with high-
throughput cell-response data to automate discovery of biochemical differences in signal
transduction among tumor and normal cell types. Apply the approach to primary human
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hepatocytes and four HCC cell lines revealed consistent differences in the apparent logic and
activities of growth factor receptor and intracellular kinase cascade in response to different
ligands. Among the inferred differences between normal and transformed cells are several
involving the strength or logic of signaling among IR, PI3K, AKT and NFκB, all molecules
that have been implicated in the development of HCC. An unexpected pharmacological
insight was the identification of Jak-Stat signaling as a target for TPCA-1, an IκB kinase
inhibitor developed to treat arthritis and airway inflammation. Detecting this
polypharmacology required comparison of a computable network model against data across
a landscape of treatment conditions, thereby allowing multi-variate effects to be linked to
specific causes. Intriguingly, TPCA-1 is significantly more potent than other IKK inhibitors
in assays for airway inflammation. Both Jak2/Stat3 and IKK/NFκB play a role in
inflammation (13, 14) and TPCA-1 would therefore appear to a “dirty” drug that is superior
to a drug that binds specifically to the nominal target (34). More generally, the approach to
modeling described in this paper may constitute a general means to study polypharmacology
that is complementary to methods for investigating drug mechanism based on transcriptional
data and protein interaction networks (35).
Our method focuses on eliminating interactions in the PKN that do not fit data. Because the
number of potential edges in an ~80 node network exceeds ~1040 it is currently impossible
to perform a comprehensive search for new edges that improve the fit to data. However, in
the current work simple inspection sufficed to identify a potential AND-gated edge
connecting IKK → Stat3 that was absent from the PKN. Implementing a rigorous approach
to finding new edges will require efficient means to search models locally or to make more
intelligent use of prior knowledge. A variety of network-inference methods other than
Boolean logic are likely to be effective for analyzing biochemical data, including differential
equations (36–38) Bayesian-networks (39) and fuzzy logic (40). Continued development of
CellNOpt on our part as well as the creation of alternative modeling approaches fostered by
efforts such as DREAM (41) is likely to improve the efficiency and accuracy of network
inference from biochemical data. Moreover, improvements in affinity capture assays, protein
arrays (42) and mass spectrometry (43, 44) should make it possible to collect much more
extensive training data than we report here.
Deep sequencing and other approaches to genome analysis support the idea that it is
networks and pathways rather than individual genes that are the functional objects of
oncogenic mutation and selection in human cancer (45). However, approaches for
constructing large-scale protein interaction graphs (4–6) are rarely cell-type specific, and
traditional ‘bottom-up’ experiments that focus on cellular responses rather than network
topologies are effective at uncovering such differences but they cannot easily incorporate
network information in a formal way. Comparative network inference is needed to close the
gap, but current efforts focus on gene regulatory networks, in large part because available
data sets involve expression signatures, gene sequences and transcription factor binding sites
(9, 46). Our results with Boolean logic and biochemical data constitute an encouraging
proof-of-principle that the biochemistry of signaling networks, including the states and
activities of proteins important in modern drug discovery, can be also be inferred and
studied systematically. Because the product of our analysis is a computable model, it is
amenable to continuous improvement and extension (with new data and interactions, for
example) in much the same way as networks inferred from genome data. In contrast, it is
difficult to account for new data using conventional, informal descriptions.
However, comparison of contemporary approaches to studying gene regulatory network in
cancer (e.g. Carro et al. (9)) with our work serves to illustrate a fundamental difference
between genome-scale data and “high throughput” biochemistry. Genomic data sets tend to
contain many data points and identifying regulatory interactions and biologically meaningful
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co-variation is a major challenge. In contrast, even “systematic” sets of biochemical data are
much smaller. However, biochemical data are also pre-selected to contain relevant signaling
information and the primary challenge is creating a framework that is effective at modeling
relatively sparse data from multiple cell types. The rather narrow purview of biochemical
models also makes it likely that many important responses are missed because they are not
measured. The future clearly lies in creating hybrid models that fuse biochemical data on
immediate early signaling with data on sequence variation, gene expression and
transcription factor binding. Such models would provide unique insight into mechanisms of
oncogenic transformation and would have practical uses in drug discovery and tumor
classification. For example, it has been demonstrated that generic PINs and PKNs represent
valuable prior knowledge for tumor classification from transcriptional profiles (47) and it
seems likely that more accurate tumor-specific hybrid “interactomes” would prove even
more useful in this context.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Experimental design and primary data
(a) Outline of the experimental approach showing five ligand cues and their receptors, 16
intracellular “signals” assayed using phospho-specific antibodies and xMAP technology (the
relevant phosphorylated residues are indicated, as are the likely upstream kinases) and three
small molecule kinase inhibitors (b) Dataset from human hepatocytes. Rows represent
intracellular signals assayed immediately prior to ligand addition and 25 minutes thereafter,
and columns represent different ligand combinations (see legend). For each combination of
ligands, one of three kinase inhibitors was applied, as well as all possible combinations of
them. Data are color-coded to highlight induction (relative to basal activity). (c) Data from
HepG2 cells following the same design as in (a). The intensity of background color for each
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box (yellow to red) indicates how the proportion of tumor cell lines that also responded to a
particular drug-ligand combination; complete data can be found in Fig. S1. Data was
processed using DataRail software (18).
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Figure 2. General workflow and goodness of fit of the cell-specific models
Schematic of workflow of model assembly, training, validation and extension. A PKN
derived from interaction data is imported into CellNOpt and converted into an assembly of
all possible logical interactions. The assembly is then trained against experimental data,
generating cell-specific models having lower MSE error. In general, this involves removing
interactions present in the PKN that are not supported by the data. Interactions absent from
the PKN can then be added to see if they reduce residual error (green line). Once a
satisfactory model is found, is is analyzed to identify differences among cell lines.
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Figure 3. Residual error (MSE deviation, see methods) of the models
(a) MSE for the ensemble of all possible models compatible with the PKN and pairwise
combinations of trained, cell-specific models with various data sets. The magnitude of the
error is mapped to the intensity of the background (with red highest). Trained models fit
corresponding data best, but all trained models exhibit lower error with all data sets than the
starting ensemble. (b) Average MSE error of models across all cell types for specific
experimental conditions and biochemical assays. For a single experiment, the error varies
between 0 and 1; the maximal error was observed for phospho-STAT3 in cells treated with
IL6 (MSE ~0.4).
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Figure 4. Inferred models of immediate-early signaling downstream in primary and transformed
hepatocytes
A graph representing nodes and edges present in a set of trained Boolean models deviating
by 1% in MSE and considered to be indistinguishable. The graph was created by exporting a
GraphML file from from ProMoT (20) and modifying it with GraphViz (48). Line thickness
denotes the frequency OR-gated edges found in trained models of primary hepatocytes
(blue) or an average of the four HCC models (red); solid black edges were found in both
primary and HCC cell lines. Thin grey edges were absent from all models, and dashed grey
edges removed in the network preprocessing step (1). Green hexagons denote stimuli, red
rectangles targets of kinase inhibitors, and blue rectangles readouts. Rectangles with
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magenta fill were both measured and subjected to inhibition using small molecule drugs.
Rectangles with white fill were compressed during graph processing. An AND gate is
present upstream of IKK only in models of primary hepatocytes (see text), no other AND
gate was consistently identified. The dashed black line denotes an interaction missing from
the starting PKN but whose inclusion reduced the MSE of both hepatocyte and HCC
models. This interaction implies inhibition of Stat3 phosphorylation by IKK in IL6-
stimulated cells (see text).
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Figure 5. Topological clustering of logic-based models of primary and transformed hepatocytes
(a) Distances between primary hepatocytes and the four HCC cell lines (Huh7, Focus,
Hep3B, and HepG2) and a ‘average HCC cell line’ (AvgHCC) based on the mean difference
in the topologies of Boolean models as defined by the distance d2 (see methods) and plotted
using the edge-weighted spring embedded algorithm in Cytoscape (49). The full range of
distances is listed in the supplementary materials. (b) Hierarchical clustering of primary and
transformed hepatocytes based on the logical models, and a comparison to previous
published clusters based on gene expression (the dendogram was manually redrawn from
reference (26) and distances are approximate). A classification of cell lines as epithelial or
mesenchymal (25) is also shown (see Fig. S8).
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Figure 6. Key differences uncovered by logic-based modeling
Schematic of inferred differences between HCC cell lines and hepatocytes. The callouts
show data associated with each topological difference with data from primary hepatocytes as
blue bars and HCC as overlaid red bars. Fold-increase in actual values are shown, except in
the case of IκB, where normalized data are compared to predictions from Boolean models
(for clarity). Numbered green circles label differences between primary and HCC, cells.
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Figure 7. Probing the biochemistry of an inferred IKK-Stat3 interaction
For in vivo experiments, cells were pretreated with 2 to 20 µM TPCA-1or BMS345541. The
concentration range of TPCA-1 was 10 fold lower than BMS345541 to match published
IC50 values for inhibition of Iκb phosphorylation. Cells were pretreated with drug for one
hour and then stimulated with IL6; the phosphorylation of Stat3Y705 was measured 25
minutes thereafter. In vitro experiments were performed with recombinant kinases and
phosphorylation levels measured using a fluorescence assay.
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